Pro Dex Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Pro Dex Inc in the fourth quarter 2026?
Pro dex Inc achieved a return on average equity (ROE) of 31.96 % in its fourth quarter 2026, this is above PDEX's average return on equity of 17.59%.
Pro Dex Inc shareholder's equity over the 12 months ending in its fourth quarter 2026 are valued at $43 million

While the company's net income was fading, Pro Dex Inc was able to improve its ROE compared to the third quarter 2026.

Within the Medical Equipment & Supplies industry 7 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 402, from total ROE ranking in the third quarter 2026 at 422.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Equity Change	30.03 %	28.1 %	18.68 %	34.45 %	-
Y / Y Net Income Change	138.68 %	20.24 %	7.21 %	89.78 %	-24.57 %
Net Income (TTM) in Millions	14	12	11	11	9
Return On Equity (TTM)	31.96 %	30.01 %	30.23 %	31.03 %	26.87 %
PDEX's Total Ranking	# 402	# 422	# 65	# 136	# 359
Equity (TTM) in Millions	48	45	37	42	37
Seq. Equity Change	5.39 %	23.38 %	-11.76 %	13.32 %	3.83 %
Seq. Net Income Change	-27.45 %	80.06 %	-53.27 %	290.98 %	-63.45 %

Back to PDEX Management Effectiveness >> PDEX's 5 Years Annual ROE >> Compare PDEX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 8
Sector	# 54
Overall	# 402

Return On Equity Statistics
High	Average	Low
45.74 %	17.59 %	-20.02 %
(Mar 31 2017)		(Jun 30 2013)

PDEX Annual Return On Equity	(Jun 30 2026) 2026	(Jun 30 2025) 2025	(Jun 30 2024) 2024	(Jun 30 2023) 2023	(Jun 30 2022) 2022
Total Equity in Millions	48	37	31	32	24
Y / Y Equity Change	30.03 %	18.68 %	-2.29 %	33.47 %	17.85 %
Net Income in Millions	14	9	2	7	4
Y / Y Net Income Change	52.17 %	322.1 %	-69.93 %	83.5 %	-13.37 %
Return On Equity	28.68 %	24.51 %	6.89 %	22.39 %	16.29 %

Back to PDEX Management Effectiveness >> PDEX's 5 Years Annual ROE >> Compare PDEX ROE to its Competitors

Annual Roe Comment

In 2026 ROE improved to 28.68 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Equipment & Supplies Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PDEX's' Return on Equity at Yahoo Finance
PDEX's Roe Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PDEX's Competitors
Subscribers only: Roe for Pro Dex Inc 's Suppliers
Subscribers only: Return On Equity for PDEX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %

Date modified: 2026-09-05T07:51:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.